Inoviq Ltd (AU:IIQ) has released an update.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
INOVIQ Ltd has made significant strides in its exosome technology, with increased adoption of its NEURO-NET and EXO-NET products by diagnostic and biopharma companies, and the successful transfer of its breast cancer monitoring test to a high-throughput platform for commercialization. The company also strengthened its corporate structure by appointing Mary Harney to its Board and completing a capital raise of $9.4 million to support ongoing development. These developments position INOVIQ as a rising player in the cancer diagnostics and neurological disease markets.
For further insights into AU:IIQ stock, check out TipRanks’ Stock Analysis page.